ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,139.83
0.75%
Dow Jones
38,239.66
0.40%
Gold vs US Dollar
2,337.935
0.00%
Brent Oil
88.165
0.00%
Bitcoin
62,917.78
-1.29%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Syndax Pharmaceuticals Inc (SNDX) Share Price

SNDX Syndax Pharmaceuticals Inc

21.06
0.49 (2.38%)
27 Apr 2024 - Closed
Delayed by 15 minutes
 Name  Symbol  Market  Type  ISIN  Description 
 Syndax Pharmaceuticals Inc NASDAQ:SNDX NASDAQ Common Stock  
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time
Upgrade Icon
 		 RN  NRN 
   0.49 2.38 21.06 20.31 21.77 21.235 20.475 20.59 775,076 23:58:01   
 Sector  Turnover  Profit  EPS - Basic  PE ratio  Mkt Cap 
 Pharmaceutical Preparations  -209.36M -2.4641 -8.55 1.79B
 Type  Size  Price  Time  Units 
 16 87,000 21.06 21:32:51 USD
 
Pre-Market and After-Hours
Recent News
DateTimeSource
HeadlineMore SNDX News
10/04/202421:05PRNUSSyndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
08/04/202412:00PRNUSSyndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
05/04/202421:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
28/03/202411:00PRNUSSyndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
26/03/202420:05PRNUSSyndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
18/03/202411:00PRNUSSyndax Announces Appointment of Steven Closter as Chief Commercial Officer
01/03/202421:05PRNUSSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Period
Draw mode
Data Downloads for SNDX

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Syndax Pharmaceuticals Inc Articles